Data gathered: November 21
AI Stock Analysis - Crispr Therapeutics (CRSP)
Analysis generated October 31, 2024. Powered by Chat GPT.
Crispr Therapeutics AG (NASDAQ: CRSP) is a leading gene-editing company, leveraging the power of the CRISPR/Cas9 technologies to create transformative gene-based medicines. The company is focused on developing innovative therapies for serious diseases, such as hemoglobinopathies, cancer, and other genetic disorders. Crispr Therapeutics is recognized for its pioneering work in gene-editing which holds the potential to revolutionize modern medicine.
Stock Alerts - Crispr Therapeutics (CRSP)
 |
Crispr Therapeutics | November 14 Price is down by -5.4% in the last 24h. |
|
Crispr Therapeutics | November 13 Web Traffic is up by 45.6% over the last month. |
|
Crispr Therapeutics | November 12 Price is down by -5.5% in the last 24h. |
|
Crispr Therapeutics | November 11 Price is up by 6.7% in the last 24h. |
Alternative Data for Crispr Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 113,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 49 | Sign up | Sign up | Sign up |
| Patents | 194 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 20 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 38,070 | Sign up | Sign up | Sign up |
| Twitter Followers | 22,169 | Sign up | Sign up | Sign up |
| Twitter Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 43 | Sign up | Sign up | Sign up |
| Business Outlook | 46 | Sign up | Sign up | Sign up |
| Linkedin Employees | 437 | Sign up | Sign up | Sign up |
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
| Price | $46.29 |
| Target Price | Sign up |
| Volume | 2,090,000 |
| Market Cap | $4.01B |
| Year Range | $44.62 - $74.5 |
| Dividend Yield | 0% |
| Analyst Rating | 53% buy |
| Industry | Biotechnology |
In the news
 |
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)November 20 - SeekingAlpha |
 |
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right NowNovember 19 - Yahoo |
 |
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Oppenheimer & Co. Inc.November 18 - ETF Daily News |
CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024November 17 - Yahoo Entertainment |
|
|
Venturi Wealth Management LLC Has $80,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)November 15 - ETF Daily News |
|
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)November 14 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 600,000 | 17M | -17M | -86M | -110M | -1.010 |
| Q2 '24 | 520,000 | 19M | -19M | -126M | -146M | -1.490 |
| Q1 '24 | 500,000 | 18M | -17M | -117M | -136M | -1.430 |
| Q4 '23 | 201M | 16M | 185M | 89M | 74M | 1.100 |
| Q3 '23 | 0 | 18M | -18M | -112M | -132M | -1.410 |
Insider Transactions View All
| Kulkarni Samarth filed to sell 226,540 shares at $46.3. October 15 '24 |
| KASINGER JAMES R. filed to sell 62,597 shares at $46.3. October 15 '24 |
| Bruno Julianne filed to sell 6,745 shares at $56.1. June 24 '24 |
| Kulkarni Samarth filed to sell 208,122 shares at $60.4. April 17 '24 |
| Kulkarni Samarth filed to sell 209,326 shares at $59.9. April 17 '24 |
Similar companies
Read more about Crispr Therapeutics (CRSP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crispr Therapeutics?
The Market Cap of Crispr Therapeutics is $4.01B.
What is the current stock price of Crispr Therapeutics?
Currently, the price of one share of Crispr Therapeutics stock is $46.29.
How can I analyze the CRSP stock price chart for investment decisions?
The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.
Does CRSP offer dividends to its shareholders?
As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crispr Therapeutics?
Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.